Note! This is an old version of B&C site.
Biopolym. Cell. 2026; 42(1):7-22.
http://dx.doi.org/10.7124/bc.000B31
Reviews
Clinically significant molecular alterations of mitochondria in carcinogenesis and age-related diseases: Part 2. Exposome influences, biomarkers and therapeutic strategies
1Gerashchenko G. V., 1Tukalo M. A.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03143

Abstract

The second part of the review presents an analysis of a number of exposome factors that influence the development of molecular disorders and metabolic shifts in mitochondria in cancer and age-related diseases. A number of mitochondrial biomarkers have been demonstrated to serve as biochemical, genetic, and molecular biological indicators for the diagnosis, prognosis, and treatment of cancer and age-related diseases. Certain areas of therapy and new modern therapeutic approaches to the treatment of cancer and age-related diseases are analyzed in the context of the pathogenetic effect on mitochondrial dysfunction in human cells and organs for the improvement of pathological conditions and the promotion of healthy longevity.
Keywords: mitochondrial dysfunction, molecular alterations, cancer, age-related diseases, exposome, biomarkers, therapeutic strategies, hormesis
Full text: (PDF, in English)

References

[1] Gerashchenko GV, Tukalo MA. Clinically significant molecular alterations of mitochondria in carcinogenesis and age-related diseases: Part 1. Disease susceptibility and diagnosic significance. Biopolym Cell. 2025; 41(4):235-50.
[2] Duarte-Hospital C, Tête A, Brial F, Benoit L, Koual M, Tomkiewicz C, Kim MJ, Blanc EB, Coumoul X, Bortoli S. Mitochondrial Dysfunction as a Hallmark of Environmental Injury. Cells. 2021; 11(1):110.
[3] Kareem MA, Ashwini A, Sunil T. The Role of the Exposome in Aging and Age-Related Diseases: A Comprehensive Review. J Pharm Bioallied Sci. 2025; 17(Suppl 1):S2-S5.
[4] Kobayashi H, Imanaka S. Understanding the impact of mitochondrial DNA mutations on aging and carcinogenesis (Review). Int J Mol Med. 2025; 56(2):118.
[5] Moro L. Mitochondrial Dysfunction in Aging and Cancer. J Clin Med. 2019; 8(11):1983.
[6] Al-Faze R, Ahmed HA, El-Atawy MA, Zagloul H, Alshammari EM, Jaremko M, Emwas AH, Nabil GM, Hanna DH. Mitochondrial dysfunction route as a possible biomarker and therapy target for human cancer. Biomed J. 2025; 48(1):100714.
[7] Shen L, Zhan X. Mitochondrial Dysfunction Pathway Alterations Offer Potential Biomarkers and Therapeutic Targets for Ovarian Cancer. Oxid Med Cell Longev. 2022; 2022:5634724.
[8] Wei P, Zhang X, Yan C, Sun S, Chen Z, Lin F. Mitochondrial dysfunction and aging: multidimensional mechanisms and therapeutic strategies. Biogerontology. 2025; 26(4):142.
[9] Bhatti JS, Kumar S, Vijayan M, Bhatti GK, Reddy PH. Therapeutic Strategies for Mitochondrial Dysfunction and Oxidative Stress in Age-Related Metabolic Disorders. Prog Mol Biol Transl Sci. 2017; 146:13-46.
[10] Wild CP. Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev. 2005; 14(8):1847-50.
[11] Vermeulen R, Schymanski EL, Barabási AL, Miller GW. The exposome and health: Where chemistry meets biology. Science. 2020; 367(6476):392-6.
[12] Bakulski KM, Blostein F, London SJ. Linking Prenatal Environmental Exposures to Lifetime Health with Epigenome-Wide Association Studies: State-of-the-Science Review and Future Recommendations. Environ Health Perspect. 2023; 131(12):126001.
[13] Hinman J, Alan JK, Lee KSS. Effects of molecular interactions between the exposome and oxylipin metabolism on healthspan. Front Physiol. 2025; 16:1584195.
[14] Pandics T, Major D, Fazekas-Pongor V, Szarvas Z, Peterfi A, Mukli P, Gulej R, Ungvari A, Fekete M, Tompa A, Tarantini S, Yabluchanskiy A, Conley S, Csiszar A, Tabak AG, Benyo Z, Adany R, Ungvari Z. Exposome and unhealthy aging: environmental drivers from air pollution to occupational exposures. Geroscience. 2023; 45(6):3381-408.
[15] Aliberti SM, Capunzo M, Galimberti D, Accardi G, Aiello A, Calabrò A, Caruso C, Candore G. Ageing Trajectories: Exposome-Driven Pathobiological Mechanisms and Implications for Prevention from Blue Zones and Italian Longevity Hotspots Such as Cilento and Sicilian Mountain Villages. Int J Mol Sci. 2025; 26(10):4796.
[16] Aliberti SM, Capunzo M. The Power of Environment: A Comprehensive Review of the Exposome's Role in Healthy Aging, Longevity, and Preventive Medicine-Lessons from Blue Zones and Cilento. Nutrients. 2025; 17(4):722.
[17] Davinelli S, Medoro A, Hu FB, Scapagnini G. Dietary polyphenols as geroprotective compounds: From Blue Zones to hallmarks of ageing. Ageing Res Rev. 2025; 108:102733.
[18] Poulain M, Herm A. Blue Zone, a Demographic Concept and Beyond. Am J Lifestyle Med. 2025; 28:15598276251342502.
[19] Aliberti SM, Capunzo M, Funk RHW. Systems and Molecular Biology of Longevity and Preventive Medicine: Brain-Energy-Microbiome-Exposome Synergies in Blue Zones and the Cilento Case. Int J Mol Sci. 2025; 26(16):7887.
[20] Neikirk K, Harris C, Le H, Oliver A, Shao B, Liu K, Beasley HK, Jamison S, Ishimwe JA, Kirabo A, Hinton A Jr. Air pollutants as modulators of mitochondrial quality control in cardiovascular disease. Physiol Rep. 2024; 12(22):e70118.
[21] Shekhar C, Khosya R, Thakur K, Mahajan D, Kumar R, Kumar S, Sharma AK. A systematic review of pesticide exposure, associated risks, and long-term human health impacts. Toxicol Rep. 2024; 13:101840.
[22] Reddam A, McLarnan S, Kupsco A. Environmental Chemical Exposures and Mitochondrial Dysfunction: a Review of Recent Literature. Curr Environ Health Rep. 2022; 9(4):631-49.
[23] Zolkipli-Cunningham Z, Falk MJ. Clinical effects of chemical exposures on mitochondrial function. Toxicology. 2017; 391:90-9.
[24] Goyal J, Rakhra G. Sedentarism and Chronic Health Problems. Korean J Fam Med. 2024; 45(5):239-57.
[25] San-Millán I. The Key Role of Mitochondrial Function in Health and Disease. Antioxidants (Basel). 2023; 12(4):782.
[26] Kenny HC, Rudwill F, Breen L, Salanova M, Blottner D, Heise T, Heer M, Blanc S, O'Gorman DJ. Bed rest and resistive vibration exercise unveil novel links between skeletal muscle mitochondrial function and insulin resistance. Diabetologia. 2017; 60(8):1491-501.
[27] Booth FW, Roberts CK, Thyfault JP, Ruegsegger GN, Toedebusch RG. Role of Inactivity in Chronic Diseases: Evolutionary Insight and Pathophysiological Mechanisms. Physiol Rev. 2017; 97(4):1351-402.
[28] Kerr J, Anderson C, Lippman SM. Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. Lancet Oncol. 2017; 18(8):e457-e471.
[29] Zhang Z, Huang Q, Zhao D, Lian F, Li X, Qi W. The impact of oxidative stress-induced mitochondrial dysfunction on diabetic microvascular complications. Front Endocrinol (Lausanne). 2023; 14:1112363.
[30] Kasprzak A. Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer. Int J Mol Sci. 2021; 22(12):6434.
[31] Morris EM, Jackman MR, Meers GM, Johnson GC, Lopez JL, MacLean PS, Thyfault JP. Reduced hepatic mitochondrial respiration following acute high-fat diet is prevented by PGC-1α overexpression. Am J Physiol Gastrointest Liver Physiol. 2013; 305(11):G868-80.
[32] Do LH, Da Costa RT, Solesio ME. Effects of nutrients and diet on mitochondrial dysfunction: An opportunity for therapeutic approaches in human disease. Biomed Pharmacother. 2025; 191:118493.
[33] Da Eira D, Jani S, Stefanovic M, Ceddia RB. Sucrose-Enriched and Carbohydrate-Free High-Fat Diets Distinctly Affect Substrate Metabolism in Oxidative and Glycolytic Muscles of Rats. Nutrients. 2024; 16(2):286.
[34] Kyriazis ID, Vassi E, Alvanou M, Angelakis C, Skaperda Z, Tekos F, Garikipati VNS, Spandidos DA, Kouretas D. The impact of diet upon mitochondrial physiology (Review). Int J Mol Med. 2022; 50(5):135.
[35] García Cobarro C, Ignez Soares L, Kutsenko Y, Tomas-Loba A. Circadian system and aging: where both times interact. Front Aging. 2025; 6:1646794.
[36] Schmitt K, Grimm A, Dallmann R, Oettinghaus B, Restelli LM, Witzig M, Ishihara N, Mihara K, Ripperger JA, Albrecht U, Frank S, Brown SA, Eckert A. Circadian Control of DRP1 Activity Regulates Mitochondrial Dynamics and Bioenergetics. Cell Metab. 2018; 27(3):657-666.e5.
[37] Takahashi JS. Transcriptional architecture of the mammalian circadian clock. Nat Rev Genet. 2017; 18(3):164-79.
[38] Rodríguez-Santana C, López-Rodríguez A, Martinez-Ruiz L, Florido J, Cela O, Capitanio N, Ramírez-Casas Y, Acuña-Castroviejo D, Escames G. The Relationship between Clock Genes, Sirtuin 1, and Mitochondrial Activity in Head and Neck Squamous Cell Cancer: Effects of Melatonin Treatment. Int J Mol Sci. 2023; 24(19):15030.
[39] Picard M, Juster RP, McEwen BS. Mitochondrial allostatic load puts the 'gluc' back in glucocorticoids. Nat Rev Endocrinol. 2014; 10(5):303-10.
[40] Picard M, McEwen BS. Psychological Stress and Mitochondria: A Conceptual Framework. Psychosom Med. 2018; 80(2):126-40.
[41] Daniels TE, Olsen EM, Tyrka AR. Stress and Psychiatric Disorders: The Role of Mitochondria. Annu Rev Clin Psychol. 2020; 16:165-86.
[42] Herbetko K, Kaczor J, Sołtyk A, Kisielewska M, Opęchowski M, Sztuder A, Kulbacka J. The Impact of Chronic Stress on Treatment Outcomes of Cancer Patients with Divergent Survival Rates: A Systematic Review. Int J Mol Sci. 2026; 27(2):686.
[43] Tini S, Baima J, Pigni S, Antoniotti V, Caputo M, De Palma E, Cerbone L, Grosso F, La Vecchia M, Bona E, Prodam F. The Microbiota-Diet-Immunity Axis in Cancer Care: From Prevention to Treatment Modulation and Survivorship. Nutrients. 2025; 17(17):2898.
[44] Jung YH, Chae CW, Han HJ. The potential role of gut microbiota-derived metabolites as regulators of metabolic syndrome-associated mitochondrial and endolysosomal dysfunction in Alzheimer's disease. Exp Mol Med. 2024; 56(8):1691-702.
[45] Zachos KA, Gamboa JA, Dewji AS, Lee J, Brijbassi S, Andreazza AC. The interplay between mitochondria, the gut microbiome and metabolites and their therapeutic potential in primary mitochondrial disease. Front Pharmacol. 2024; 15:1428242.
[46] Argentieri MA, Amin N, Nevado-Holgado AJ, Sproviero W, Collister JA, Keestra SM, Kuilman MM, Ginos BNR, Ghanbari M, Doherty A, Hunter DJ, Alvergne A, van Duijn CM. Integrating the environmental and genetic architectures of aging and mortality. Nat Med. 2025; 31(3):1016-25.
[47] Murillo Carrasco AG, Chammas R, Furuya TK. Mitochondrial DNA alterations in precision oncology: Emerging roles in diagnostics and therapeutics. Clinics (Sao Paulo). 2025; 80:100570.
[48] Mou J, Zhang M, Qin F, Cui Y, Xu K, Pang B, Li X, Tan W, Yang A, Liu Y, Shen L, Liu Y, Xu K. A multi-cohort validated OXPHOS signature predicts survival and immune profiles in grade II/III glioma patients. Front Immunol. 2025; 16:1638824.
[49] Eniafe J, Jiang S. The functional roles of TCA cycle metabolites in cancer. Oncogene. 2021; 40(19):3351-63.
[50] Sarkar S, Chang CI, Jean J, Wu MJ. TCA cycle-derived oncometabolites in cancer and the immune microenvironment. J Biomed Sci. 2025; 32(1):87.
[51] Sharma E, Fotooh Abadi L, Kombe Kombe JA, Kandala M, Parker J, Winicki N, Kelesidis T. Overview of methods that determine mitochondrial function in human disease. Metabolism. 2025; 170:156300.
[52] Peng F, Wang S, Feng Z, Zhou K, Zhang H, Guo X, Xing J, Liu Y. Circulating cell-free mtDNA as a new biomarker for cancer detection and management. Cancer Biol Med. 2023; 21(2):105-10.
[53] Mete O, Wenig BM. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms. Head Neck Pathol. 2022; 16(1):123-42.
[54] Degenhardt J, Tolkach Y, Amin MB, Mosiello G, Ertoy Baydar D, Cornec-Le Gall E, DiCola J, Elhag D, Frezza C, Halbritter J, Blanco I, Jewett MAS, Lattouf JB, Lovitt G, Lundgren PO, Maher ER, Mulders P, Shuch B, Hartmann A, Müller RU. The impact of the new WHO classification of renal cell carcinoma on the diagnosis of hereditary leiomyomatosis and renal cell carcinoma. Nephrol Dial Transplant. 2025; 40(7):1428-32.
[55] Garg P, Singhal G, Horne D, Kulkarni P, Salgia R, Singhal SS. Molecular PET imaging: Unlocking the secrets of cancer metabolism. Biochem Pharmacol. 2025; 242(Pt 3):117202.
[56] Yu SL, Xu LT, Qi Q, Geng YW, Chen H, Meng ZQ, Wang P, Chen Z. Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy. Sci Rep. 2017; 7:45194.
[57] Gu S, Yang C. Serum lactate dehydrogenase level predicts the prognosis in bladder cancer patients. BMC Urol. 2023; 23(1):65.
[58] Nakagawa M, Yamaguchi M, Endo M, Machida Y, Hattori A, Tanzawa F, Tsutsumi S, Kitabayashi I, Kawai A, Nakatani F. Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma. J Bone Oncol. 2022; 34:100430.
[59] Zhang W, Lang R. Succinate metabolism: a promising therapeutic target for inflammation, ischemia/reperfusion injury and cancer. Front Cell Dev Biol. 2023; 11:1266973.
[60] Eijkelenkamp K, Osinga TE, Links TP, van der Horst-Schrivers ANA. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers. Clin Genet. 2020; 97(1):39-53.
[61] Mu X, Zhao T, Xu C, Shi W, Geng B, Shen J, Zhang C, Pan J, Yang J, Hu S, Lv Y, Wen H, You Q. Oncometabolite succinate promotes angiogenesis by upregulating VEGF expression through GPR91-mediated STAT3 and ERK activation. Oncotarget. 2017; 8(8):13174-85.
[62] Gao Y, Fan S, Sun X, Li J, Dai Y, Li H, Ma H, Xu Y, Lv L. Oncometabolite fumarate facilitates PD-L1 expression and immune evasion in clear cell renal cell carcinoma. Cell Death Dis. 2025; 16(1):432.
[63] Bancel LP, Masso V, Dessein AF, Aubert S, Leteurtre E, Coppin L, Odou MF, Do Cao C, Cardot-Bauters C, Pigny P. Serum Succinate/Fumarate Ratio in Patients With Paraganglioma/Pheochromocytoma Attending an Endocrine Oncogenetic Unit. J Clin Endocrinol Metab. 2023; 108(9):2343-52.
[64] Wang J, Yuan T, Yang B, He Q, Zhu H. SDH defective cancers: molecular mechanisms and treatment strategies. Cell Biol Toxicol. 2025; 41(1):74.
[65] D'Indinosante M, Lardino S, Bruno M, Stabile G, Pavone M, Giannone G, Lombardi P, Daniele G, Fanfani F, Ciccarone F, Scambia G. Implications of Fumarate Hydratase Deficiency (FHD) and Cancer Risk: A Window into the Clinical and Oncological Implications of a Rare Disorder in Gynecology. Cancers (Basel). 2025; 17(4):573.
[66] Murugan AK, Alzahrani AS. Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas. Br J Biomed Sci. 2022; 79:10208.
[67] Winter M, Ebner S, Scheuber N, Schulze F, Kinzler MN, Walter D, Wild PJ. Evaluation of an IDH1/2 Mutation FastTrack Assay for Patients with Cholangiocarcinoma. Cancers (Basel). 2025; 17(5):820.
[68] Shayota BJ. Biomarkers of mitochondrial disorders. Neurotherapeutics. 2024; 21(1):e00325.
[69] Maresca A, Del Dotto V, Romagnoli M, La Morgia C, Di Vito L, Capristo M, Valentino ML, Carelli V; ER-MITO Study Group. Expanding and validating the biomarkers for mitochondrial diseases. J Mol Med (Berl). 2020; 98(10):1467-78.
[70] Burtscher J, Soltany A, Visavadiya NP, Burtscher M, Millet GP, Khoramipour K, Khamoui AV. Mitochondrial stress and mitokines in aging. Aging Cell. 2023; 22(2):e13770.
[71] Nguyen NNY, Kim SS, Jo YH. Deregulated Mitochondrial DNA in Diseases. DNA Cell Biol. 2020; 39(8):1385-400.
[72] Shelton SD, House S, Martins Nascentes Melo L, Ramesh V, Chen Z, Wei T, Wang X, Llamas CB, Venigalla SSK, Menezes CJ, Allies G, Krystkiewicz J, Rösler J, Meckelmann SW, Zhao P, Rambow F, Schadendorf D, Zhao Z, Gill JG, DeBerardinis RJ, Morrison SJ, Tasdogan A, Mishra P. Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis. Sci Adv. 2024; 10(44):eadk8801.
[73] Ito R, Yashiro M, Tsukioka T, Izumi N, Komatsu H, Inoue H, Yamamoto Y, Nishiyama N. GLUT1 and PKM2 may be useful prognostic predictors in patients with non‑small cell lung cancer following curative R0 resection. Oncol Lett. 2023; 25(3):129.
[74] Jiang X, Xia Y, Meng H, Liu Y, Cui J, Huang H, Yin G, Shi B. Identification of a Nuclear Mitochondrial-Related Multi-Genes Signature to Predict the Prognosis of Bladder Cancer. Front Oncol. 2021; 11:746029.
[75] Zhu S, Chen C, Wang M, Liu Y, Li B, Qi X, Song M, Liu X, Feng J, Liu J. Pan-cancer association of a mitochondrial function score with genomic alterations and clinical outcome. Sci Rep. 2024; 14(1):31430.
[76] Thirunavukkarasu S, Banerjee S, Tantray I, Ojha R. Non-coding RNA and reprogrammed mitochondrial metabolism in genitourinary cancer. Front Genet. 2024; 15:1364389.
[77] Haoming L, Rui W, Mao H, Fan J, Li Z, Xin S, Hong R. Mitochondrial non-coding RNAs as novel biomarkers and therapeutic targets in lung cancer integration of traditional bioinformatics and machine learning approaches. Front Oncol. 2025; 15:1690077.
[78] Ma Z, Wang R, Yuan M, Wang B, Li L, Zhao T, Zhao X. Machine learning-enhanced discovery of tsRNA-mRNA regulatory networks: identifying novel diagnostic biomarkers and therapeutic targets in breast cancer. Front Pharmacol. 2025; 16:1640192.
[79] Stoccoro A, Coppedè F. Mitochondrial epigenetic mechanisms in cancer: an updated overview. Front Cell Dev Biol. 2026; 13:1720652.
[80] Liu Y, Chen C, Wang X, Sun Y, Zhang J, Chen J, Shi Y. An Epigenetic Role of Mitochondria in Cancer. Cells. 2022; 11(16):2518.
[81] Delaunay S, Pascual G, Feng B, Klann K, Behm M, Hotz-Wagenblatt A, Richter K, Zaoui K, Herpel E, Münch C, Dietmann S, Hess J, Benitah SA, Frye M. Mitochondrial RNA modifications shape metabolic plasticity in metastasis. Nature. 2022; 607(7919):593-603.
[82] Boulton DP, Caino MC. Mitochondrial Fission and Fusion in Tumor Progression to Metastasis. Front Cell Dev Biol. 2022; 10:849962.
[83] Zhao J, Cui M, Yao X, Jiang Z, Qi L, Chen J, Fan C, Bai S, Zhou C, Wei R, Liu H, Yang Q, Wan L, Bao D. Targeting TFAM downregulation mediated mtDNA-NLRP3 pathway suppresses TAM infiltration and HCC progression. Oncogene. 2025; 44(33):2956-69.
[84] Chen S, Xu Y, Zhuo W, Zhang L. The emerging role of lactate in tumor microenvironment and its clinical relevance. Cancer Lett. 2024; 590:216837.
[85] Li X, Liu X, Chen X, Wang Y, Wu S, Li F, Su Y, Chen L, Xiao J, Ma J, Qin P. Leukocyte mitochondrial DNA copy number and cardiovascular disease: A systematic review and meta-analysis of cohort studies. iScience. 2024; 27(9):110522.
[86] Qin P, Chen X, Ma P, Li X, Lin Y, Liu X, Liang X, Qin T, Liang J, Ouyang J. Mitochondrial DNA copy number and Alzheimer's disease and Parkinson disease. Mitochondrion. 2025; 83:102032.
[87] Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Front Endocrinol (Lausanne). 2023; 14:1120533.
[88] Sivakumar R, Senghor KAA, Vinodhini VM, Kumar J. Mitochondrial-Derived Peptides as Therapeutics and Biomarkers for Combating Vascular Aging and Associated Cardiovascular Diseases. Curr Cardiol Rev. 2025.
[89] Huang Q, Trumpff C, Monzel AS, Rausser S, Devine J, Liu CC, Kelly C, Kurade M, Li S, Engelstad K, Tanji K, Lauriola V, Wang T, Wang S, Sloan R, Juster RP, Hirano M, Picard M. The mitochondrial disease biomarker GDF15 is dynamic, quantifiable in saliva, and correlates with disease severity. Mol Genet Metab. 2025; 145(4):109179.
[90] Shu H, Li R, Tang X, Zhang Q. A mitochondrial-related gene signature predicts prognosis and immunotherapy response in hepatocellular carcinoma. Sci Rep. 2025; 15(1):25435.
[91] Zhang S, Guo H, Wang H, Liu X, Wang M, Liu X, Fan Y, Tan K. A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma. Apoptosis. 2024; 29(5-6):768-84.
[92] Du H, Xu T, Yu S, Wu S, Zhang J. Mitochondrial metabolism and cancer therapeutic innovation. Signal Transduct Target Ther. 2025; 10(1):245.
[93] Passaniti A, Kim MS, Polster BM, Shapiro P. Targeting mitochondrial metabolism for metastatic cancer therapy. Mol Carcinog. 2022; 61(9):827-38.
[94] Mukherjee S, Bhatti GK, Chhabra R, Reddy PH, Bhatti JS. Targeting mitochondria as a potential therapeutic strategy against chemoresistance in cancer. Biomed Pharmacother. 2023; 160:114398.
[95] Kumar S, Ashraf R, C K A. Mitochondrial dynamics regulators: implications for therapeutic intervention in cancer. Cell Biol Toxicol. 2022; 38(3):377-406.
[96] Chen K, Ernst P, Sarkar A, Kim S, Si Y, Varadkar T, Ringel MD, Liu XM, Zhou L. mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer. Cancer Res. 2024; 84(23):4049-65.
[97] Hornsby BD, Tuekpe JKK, Steele CA, Devereaux AA, Bowman KER, Lim CS. Mitochondrially Targeted p53-Bad* Fusion Gene Therapy Promotes Apoptosis in Hepatocellular Carcinoma by Pan-Bcl-2 Inhibition. Mol Pharm. 2025; 22(9):5652-68.
[98] Kazemian P, Yu SY, Thomson SB, Birkenshaw A, Leavitt BR, Ross CJD. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components. Mol Pharm. 2022; 19(6):1669-86.
[99] Begelman DV, Dixit B, Truong C, King CD, Watson MA, Schilling B, Brand MD, Boominathan A. Exogenous expression of ATP8, a mitochondrial encoded protein, from the nucleus in vivo. Mol Ther Methods Clin Dev. 2024; 32(4):101372.
[100] Lim K. Mitochondrial genome editing: strategies, challenges, and applications. BMB Rep. 2024; 57(1):19-29.
[101] Yang MQ, Zhang SL, Sun L, Huang LT, Yu J, Zhang JH, Tian Y, Han CB, Ma JT. Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells. Mol Cancer. 2024; 23(1):260.
[102] Li H, Jin W, Liu J, Zhou Y, Shan X, Zhang Y, Kou Y, Deng C, Jin C, Kuang J, Lau YL, Conde J, Huang B, Lin Q. Optimizing mitochondria function in immune cells: implications for cancer immunotherapy. Trends Cancer. 2025; 11(12):1170-84.
[103] Li R, Li Y. Role of metabolic reprogramming of cancer‑associated fibroblasts in tumor development and progression (Review). Int J Oncol. 2025; 67(5):90.
[104] Yusri K, Jose S, Vermeulen KS, Tan TCM, Sorrentino V. The role of NAD+ metabolism and its modulation of mitochondria in aging and disease. NPJ Metab Health Dis. 2025; 3(1):26.
[105] Radovic M, Gartzke LP, Wink SE, van der Kleij JA, Politiek FA, Krenning G. Targeting the Electron Transport System for Enhanced Longevity. Biomolecules. 2025; 15(5):614.
[106] Lelarge V, Capelle R, Oger F, Mathieu T, Le Calvé B. Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment. NPJ Aging. 2024; 10(1):12.
[107] Seyfried TN, Chinopoulos C. Can the Mitochondrial Metabolic Theory Explain Better the Origin and Management of Cancer than Can the Somatic Mutation Theory? Metabolites. 2021; 11(9):572.
[108] Duraj T, Kalamian M, Zuccoli G, Maroon JC, D'Agostino DP, Scheck AC, Poff A, Winter SF, Hu J, Klement RJ, Hickson A, Lee DC, Cooper I, Kofler B, Schwartz KA, Phillips MCL, Champ CE, Zupec-Kania B, Tan-Shalaby J, Serfaty FM, Omene E, Arismendi-Morillo G, Kiebish M, Cheng R, El-Sakka AM, Pflueger A, Mathews EH, Worden D, Shi H, Cincione RI, Spinosa JP, Slocum AK, Iyikesici MS, Yanagisawa A, Pilkington GJ, Chaffee A, Abdel-Hadi W, Elsamman AK, Klein P, Hagihara K, Clemens Z, Yu GW, Evangeliou AE, Nathan JK, Smith K, Fortin D, Dietrich J, Mukherjee P, Seyfried TN. Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma. BMC Med. 2024; 22(1):578.
[109] Zhang M, Zhang Q, Huang S, Lu Y, Peng M. Impact of ketogenic diets on cancer patient outcomes: a systematic review and meta-analysis. Front Nutr. 2025; 12:1535921.
[110] Uzun AB, Iliescu MG, Stanciu LE, Ionescu EV, Ungur RA, Ciortea VM, Irsay L, Motoașcă I, Popescu MN, Popa FL, Pazara L, Tofolean DE. Effectiveness of Intermittent Hypoxia-Hyperoxia Therapy in Different Pathologies with Possible Metabolic Implications. Metabolites. 2023; 13(2):181.
[111] Wang S, Peng P, Wang J, Zhang Z, Liu P, Xu LX. Cryo-thermal therapy reshaped the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy. Cancer Immunol Immunother. 2024; 74(1):21.
[112] Smadja DM. Hyperthermia for Targeting Cancer and Cancer Stem Cells: Insights from Novel Cellular and Clinical Approaches. Stem Cell Rev Rep. 2024; 20(6):1532-9.
[113] Chen X, Zhang J, Gao F, Liu N, Du H, Li J, Li Z, Chen R. Exercise therapy: an effective approach to mitigate the risk of cancer metastasis. World J Surg Oncol. 2025; 23(1):192.
[114] Smith-Turchyn J, Sabiston CM, Edward H, Richardson J, Nayiga BK, Page A, Brooks D, Mukherjee SD. Implementing physical activity for individuals with cancer during treatment: protocol for the IMPACT implementation-effectiveness trial. BMJ Open. 2025; 15(3):e101013.
[115] Brandes M, Berling-Ernst A, Baurecht H, Jensen W, Götte M, Herrmann A, Fuhr D, Schmidt H, Lucas A, Madl B, Elmers S, Schmidt T, Welker C, Golla A, Wehner A, Morlok D, Rueter J, Meuer J, Reitz M, Kersten J, Zimmer R, Gadczikowske Y, Stark R, Hegenberg K, Laxy M, Halle M, Jahn P, Bokemeyer C, Theurich S, Zeeb H, Leitzmann M, Baumann FT; IMPLEMENT consortium. Advancing the implementation of quality-assured oncological exercise therapy in Germany: protocol for the IMPLEMENT project. BMC Cancer. 2025; 25(1):710.
[116] Al Balah OF, Rafie M, Osama AR. Immunomodulatory effects of photobiomodulation: a comprehensive review. Lasers Med Sci. 2025; 40(1):187.
[117] Stringer EJ, Cloke RWG, Van der Meer L, Murphy RA, Macpherson NA, Lum JJ. The Clinical Impact of Time-restricted Eating on Cancer: A Systematic Review. Nutr Rev. 2025; 83(7):e1660-e1676.
[118] Xu Y, Gao Z, Liu J, Yang Q, Xu S. Role of gut microbiome in suppression of cancers. Gut Microbes. 2025; 17(1):2495183.
[119] Bautista J, Villegas-Chávez JA, Bunces-Larco D, Martín-Aguilera R, López-Cortés A. The microbiome as a therapeutic co-driver in melanoma immuno-oncology. Front Med (Lausanne). 2025; 12:1673880.
[120] Prajapati SK, Shah R, Alford N, Mishra SP, Jain S, Hansen B, Sanberg P, Molina AJA, Yadav H. The Triple Alliance: Microbiome, Mitochondria, and Metabolites in the Context of Age-Related Cognitive Decline and Alzheimer's Disease. J Gerontol A Biol Sci Med Sci. 2023; 78(12):2187-202.
[121] Kadyan S, Park G, Singh TP, Patoine C, Singar S, Heise T, Domeier C, Ray C, Kumar M, Behare PV, Chakrabarty P, Efron P, Sheffler J, Nagpal R. Microbiome-based therapeutics towards healthier aging and longevity. Genome Med. 2025; 17(1):75.